OTC · Financial Statements
Astellas Pharma Inc. (ALPMF) Financial Statements
$12.85
OTC: ALPMF
Market Cap $23.02B
Overview Financials Dividend Astellas Pharma Inc. most recently reported annual revenue of $2.15T, net profit of $293.4B, revenue has compounded at 11.5% a year over the last five years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2022 2023 2024 2025 2026 Revenue $1.30T $1.52T $1.60T $1.91T $2.15T Operating Profit $220.0B $133.0B $25.5B $41.0B $422.3B Net Profit $124.1B $98.7B $17.0B $50.7B $293.4B EPS $67.05 $54.09 $9.47 $28.24 $162.98 Op Margin 17.0% 8.8% 1.6% 2.1% 19.6%
Balance Sheet (USD)
Metric 2022 2023 2024 2025 2026 Total Assets $2.33T $2.46T $3.57T $3.34T $3.59T Total Liabilities $872.1B $948.6B $1.97T $1.83T $1.75T Cash $316.0B $376.8B $335.7B $188.4B $283.4B Borrowings $212.7B $200.0B $1.01T $831.4B $569.5B
Cash Flow (USD)
Metric 2022 2023 2024 2025 2026 Operating Cash Flow $257.4B $327.8B $172.5B $194.5B $569.8B Investing Cash Flow $-138.9B $-173.0B $-928.3B $-146.7B $-131.3B Financing Cash Flow $-71.1B $-80.3B $-40.5B $-43.9B $-1.3B Net Cash Flow $-10.1B $60.9B $-41.2B $-147.3B $82.7B Free Cash Flow $181.0B $239.2B $90.0B $137.2B $511.7B
Valuation & Return Ratios
Metric Value PEG Ratio 0.03 EV / EBITDA 6.96 FCF Yield 13.22% Quick Ratio 0.90 Interest Coverage 28.77 Return 1Y 34.13% Return 3Y 9.70% Return 5Y 2.17%
Screens featuring this stock